Agenda
3:00-3:30 PM Networking & Registration
3:30-5:00 PM Expert Panel
5:00-6:30 PM Networking Reception

We have seen significant changes in M&A activity in the life sciences industry, but how does that affect the future of your company and the industry as a whole? Has M&A stalled or are deals fewer and far between but larger in scope? Alternatively, has the pace quickened but with monumental changes to the structure of a deal? Most importantly, how can you position your company to make acquisition an attractive option?

Join this panel to hear M&A strategy perspective from the acquirer and the acquired, the investor, the banker, and the lawyer.

You will have the opportunity to meet Peter McWilliams, Ph.D., Principal at Sanderling Ventures, and Chairman & Acting CEO of Actimis, a biopharmaceutical company currently being acquired by World Bio-giant Boehringer Ingelheim GmbH for as much as $515 million.

You will learn:
- How to identify the good target buyer, and how to approach him
- Valuation challenges and strategies
- Is M&A your best bet
- How to structure the deal
- What to expect after the acquisition
- What are the relative advantages of pursuing a M&A over other transactions
- What are the risks of a M&A and how to mitigate theses risks
- How to plan a successful exit.

Regular $40 | Partners' Network $30 | Members: Free | Networking Reception only: $20 | Door Registration: add $10.

• Add to calendar
• Invite Friends
• Print